Drug
Concizumab clinical trials
Also written NNC172-2021.
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses concizumab is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without InhibitorsActive, not recruitingPhase 3Novo Nordisk A/SNCT05135559Written as Concizumab
- Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without InhibitorsActive, not recruitingPhase 3Novo Nordisk A/SNCT04082429Written as Concizumab
- Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With InhibitorsActive, not recruitingPhase 3Novo Nordisk A/SNCT04083781Written as Concizumab
- A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without InhibitorsCompletedPhase 2Novo Nordisk A/SNCT03196297Written as Concizumab
- A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With InhibitorsCompletedPhase 2Novo Nordisk A/SNCT03196284Written as Concizumab
- Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or BCompletedPhase 1Novo Nordisk A/SNCT01228669Written as NNC 0172-0000-2021
- A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia SubjectsTerminatedPhase 1Novo Nordisk A/SNCT01631942Written as NNC172-2021
- Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A SubjectsCompletedPhase 1Novo Nordisk A/SNCT02490787Written as Concizumab
- Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese SubjectsCompletedPhase 1Novo Nordisk A/SNCT01555749Written as NNC172-2021
Codes
What other systems call concizumab · ClinicalTrials.gg INT006124
- MeSH (NLM) C574488concizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 68603V9EAFCONCIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q104153457concizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166914ConcizumabOne source FDA
- DrugBank DB12820One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C574488 | concizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 68603V9EAF | CONCIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q104153457 | concizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166914 | Concizumab | One source FDA |
| DrugBank | DB12820 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.